Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Sciences|May 27, 2023
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA BiomarkersStefania Bellone, Blair McNamara, Levent Mutlu, et al.
Gynecologic Oncology|May 7, 2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analysesVictoria M Ettorre, Stefania Bellone, Michelle Greenman, et al.
Gynecologic Oncology|July 9, 2024
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinomaBlair McNamara, Michelle Greenman, Stefania Bellone, et al.
Cancer Research Communications|August 27, 2025
Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomasNiccolo G Santin, Namrata Sethi, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine CancerAlessandro D Santin, Dana M Roque, Eric Siegel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 14, 2026
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort studyYasmin Abozenah, Hadi Erfani, Carolyn Haunschild, et al.
Gynecologic Oncology|June 29, 2025
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcomaMichelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Cancer Medicine|September 6, 2024
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancerTobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, et al.
Cancer Research Communications|April 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous CarcinomaMichelle Greenman, Cem Demirkiran, Stefania Bellone, et al.
Gynecologic Oncology|May 4, 2024
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomasCem Demirkiran, Michelle Greenman, Stefania Bellone, et al.
Pageof 5